Cargando…

Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment

Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. However, patients are more satisfied with biologicals than with other treatments. The aim of our study was to assess patient pref...

Descripción completa

Detalles Bibliográficos
Autores principales: Kromer, Christian, Schaarschmidt, Marthe-Lisa, Schmieder, Astrid, Herr, Raphael, Goerdt, Sergij, Peitsch, Wiebke K.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Public Library of Science 2015
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461256/
https://www.ncbi.nlm.nih.gov/pubmed/26058083
http://dx.doi.org/10.1371/journal.pone.0129120
_version_ 1782375504994631680
author Kromer, Christian
Schaarschmidt, Marthe-Lisa
Schmieder, Astrid
Herr, Raphael
Goerdt, Sergij
Peitsch, Wiebke K.
author_facet Kromer, Christian
Schaarschmidt, Marthe-Lisa
Schmieder, Astrid
Herr, Raphael
Goerdt, Sergij
Peitsch, Wiebke K.
author_sort Kromer, Christian
collection PubMed
description Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. However, patients are more satisfied with biologicals than with other treatments. The aim of our study was to assess patient preferences for treatment of psoriasis with biologicals by using computer-based conjoint analysis. Biologicals approved for psoriasis in Germany were decomposed into outcome (probability of 50% and 90% improvement, time until response, sustainability of success, probability of mild and severe adverse events (AE), probability of American College of Rheumatology (ACR) 20 response) and process attributes (treatment location, frequency, duration and delivery method). Impact of sociodemographic and socioeconomic characteristics and disease severity on Relative Importance Scores (RIS) of each attribute was assessed with analyses of variance, post hoc tests, and multivariate regression. Averaged across the cohort of 200 participants with moderate-to-severe psoriasis, preferences were highest for avoiding severe AE (RIS = 17.3), followed by 90% improvement (RIS = 14.0) and avoiding mild AE (RIS = 10.5). Process attributes reached intermediate RIS (8.2–8.8). Men were more concerned about efficacy than women (50% improvement: RIS = 6.9 vs. 9.5, p = 0.008; β = -0.191, p = 0.011 in multivariate models; 90% improvement: RIS = 12.1 vs. 15.4, p = 0.002; β = -0.197, p = 0.009). Older participants judged the probability of 50% and 90% improvement less relevant than younger ones (50% improvement: Pearson’s Correlation (PC) = -0.161, p = 0.022; β = -0.219, p = 0.017; 90% improvement: PC = -0.155, p = 0.028; β = -0.264, p = 0.004) but worried more about severe AE (PC = 0.175, p = 0.013; β = 0.166, p = 0.082). In summary, participants with moderate-to-severe psoriasis were most interested in safety of biologicals, followed by efficacy, but preferences varied with sociodemographic characteristics and working status. Based on this knowledge, physicians should identify preferences of each individual patient during shared decision-making in order to optimize treatment satisfaction, adherence and outcome.
format Online
Article
Text
id pubmed-4461256
institution National Center for Biotechnology Information
language English
publishDate 2015
publisher Public Library of Science
record_format MEDLINE/PubMed
spelling pubmed-44612562015-06-16 Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment Kromer, Christian Schaarschmidt, Marthe-Lisa Schmieder, Astrid Herr, Raphael Goerdt, Sergij Peitsch, Wiebke K. PLoS One Research Article Treatment dissatisfaction and non-adherence are common among patients with psoriasis, partly due to discordance between individual preferences and recommended treatments. However, patients are more satisfied with biologicals than with other treatments. The aim of our study was to assess patient preferences for treatment of psoriasis with biologicals by using computer-based conjoint analysis. Biologicals approved for psoriasis in Germany were decomposed into outcome (probability of 50% and 90% improvement, time until response, sustainability of success, probability of mild and severe adverse events (AE), probability of American College of Rheumatology (ACR) 20 response) and process attributes (treatment location, frequency, duration and delivery method). Impact of sociodemographic and socioeconomic characteristics and disease severity on Relative Importance Scores (RIS) of each attribute was assessed with analyses of variance, post hoc tests, and multivariate regression. Averaged across the cohort of 200 participants with moderate-to-severe psoriasis, preferences were highest for avoiding severe AE (RIS = 17.3), followed by 90% improvement (RIS = 14.0) and avoiding mild AE (RIS = 10.5). Process attributes reached intermediate RIS (8.2–8.8). Men were more concerned about efficacy than women (50% improvement: RIS = 6.9 vs. 9.5, p = 0.008; β = -0.191, p = 0.011 in multivariate models; 90% improvement: RIS = 12.1 vs. 15.4, p = 0.002; β = -0.197, p = 0.009). Older participants judged the probability of 50% and 90% improvement less relevant than younger ones (50% improvement: Pearson’s Correlation (PC) = -0.161, p = 0.022; β = -0.219, p = 0.017; 90% improvement: PC = -0.155, p = 0.028; β = -0.264, p = 0.004) but worried more about severe AE (PC = 0.175, p = 0.013; β = 0.166, p = 0.082). In summary, participants with moderate-to-severe psoriasis were most interested in safety of biologicals, followed by efficacy, but preferences varied with sociodemographic characteristics and working status. Based on this knowledge, physicians should identify preferences of each individual patient during shared decision-making in order to optimize treatment satisfaction, adherence and outcome. Public Library of Science 2015-06-09 /pmc/articles/PMC4461256/ /pubmed/26058083 http://dx.doi.org/10.1371/journal.pone.0129120 Text en © 2015 Kromer et al http://creativecommons.org/licenses/by/4.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original author and source are properly credited.
spellingShingle Research Article
Kromer, Christian
Schaarschmidt, Marthe-Lisa
Schmieder, Astrid
Herr, Raphael
Goerdt, Sergij
Peitsch, Wiebke K.
Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
title Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
title_full Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
title_fullStr Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
title_full_unstemmed Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
title_short Patient Preferences for Treatment of Psoriasis with Biologicals: A Discrete Choice Experiment
title_sort patient preferences for treatment of psoriasis with biologicals: a discrete choice experiment
topic Research Article
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC4461256/
https://www.ncbi.nlm.nih.gov/pubmed/26058083
http://dx.doi.org/10.1371/journal.pone.0129120
work_keys_str_mv AT kromerchristian patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment
AT schaarschmidtmarthelisa patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment
AT schmiederastrid patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment
AT herrraphael patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment
AT goerdtsergij patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment
AT peitschwiebkek patientpreferencesfortreatmentofpsoriasiswithbiologicalsadiscretechoiceexperiment